{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:51:16Z","timestamp":1744199476135},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11596-021-2363-9","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T04:05:17Z","timestamp":1622174717000},"page":"581-586","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-na\u00efve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection"],"prefix":"10.1007","volume":"41","author":[{"given":"Manar","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azza E.","family":"Mansey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engy A.","family":"Wahsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoda M.","family":"Rabea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"issue":"1","key":"2363_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/liv.13186","volume":"37","author":"A Kandeel","year":"2017","unstructured":"Kandeel A, Genedy M, El-Refai S, et al. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int, 2017,37(1):45\u201353","journal-title":"Liver Int"},{"key":"2363_CR2","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Black S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol, 2014,61(1 Suppl):S45\u2013S57","journal-title":"J Hepatol"},{"issue":"1","key":"2363_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/1871526518666180716141806","volume":"20","author":"EA Wahsh","year":"2020","unstructured":"Wahsh EA, Hussein AK, Gomaa AA, et al. Real life Egyptian experience of daclatasvir plus sofosbuvir with Ribavirin in Na\u00efve difficult to treat HCV patients. Infect Disord Drug Targets, 2020,20(1):43\u201348","journal-title":"Infect Disord Drug Targets"},{"issue":"1","key":"2363_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"EASL","year":"2017","unstructured":"EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol, 2017,66(1):153\u2013194","journal-title":"J Hepatol"},{"issue":"5","key":"2363_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3851\/IMP3083","volume":"22","author":"H Ahmed","year":"2017","unstructured":"Ahmed H, Ahmed E, Abushouk AI, et al. Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis. Antivir Ther, 2017,22(5):369\u2013379","journal-title":"Antivir Ther"},{"issue":"2","key":"2363_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jiph.2017.09.004","volume":"11","author":"H Ahmed","year":"2018","unstructured":"Ahmed H, Abushouk AI, Attia A, et al. Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: a systematic review and meta-analysis. J Infect Public Heal, 2018,11(2):156\u2013164","journal-title":"J Infect Public Heal"},{"issue":"1","key":"2363_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5604\/01.3001.0010.7532","volume":"17","author":"H Ahmed","year":"2018","unstructured":"Ahmed H, Abushouk AI, Menshawy A, et al. Meta-analysis of grazoprevir plus elbasvir for treatment of hepatitis C virus genotype 1 infection. Ann Hepatol, 2018,17(1):18\u201332","journal-title":"Ann Hepatol"},{"issue":"Suppl 1","key":"2363_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/liv.13027","volume":"36","author":"T Asselah","year":"2016","unstructured":"Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int, 2016,36(Suppl 1):47\u201357","journal-title":"Liver Int"},{"issue":"Suppl 2","key":"2363_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","volume":"31","author":"W Sievert","year":"2011","unstructured":"Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int, 2011,31(Suppl 2):61\u201380","journal-title":"Liver Int"},{"issue":"3","key":"2363_CR10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1086\/315786","volume":"182","author":"SC Ray","year":"2000","unstructured":"Ray SC, Arthur RR, Carella A, et al. Genetic Epidemiology of Hepatitis C Virus throughout Egypt. J Infect Dis, 2000,182(3):698\u2013707","journal-title":"J Infect Dis"},{"issue":"2","key":"2363_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1128\/AAC.04226-14","volume":"59","author":"P Krishnan","year":"2015","unstructured":"Krishnan P, Beyer J, Mistry N, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother, 2015,59(2):979\u2013987","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2363_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/liv.13067","volume":"36","author":"F Poordad","year":"2016","unstructured":"Poordad F, Landis CS, Asatryan A, et al. High antiviral activity of NS 5A inhibitor ABT-530 with paritaprevir\/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int, 2016,36(8):1125\u20131132","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"2363_CR13","first-page":"716A","volume":"62","author":"P Pockros","year":"2015","unstructured":"Pockros P, Reddy R, Mantry P, et al. RUBY-I: ombitasvir\/paritaprevir\/ritonavir+ dasabuvir+\/-ribavirin in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal disease. Hepatology, 2015,62(Suppl 1):716A","journal-title":"Hepatology"},{"issue":"2","key":"2363_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s13318-016-0341-6","volume":"42","author":"AR Polepally","year":"2017","unstructured":"Polepally AR, Badri PS, Eckert D, et al. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection. Eur J Drug Metab Pharmacokinet, 2017,42(2):333\u2013339","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"2363_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"JM Pawlotsky","year":"2016","unstructured":"Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology, 2016,151(1):70\u201386","journal-title":"Gastroenterology"},{"issue":"2","key":"2363_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5114\/ceh.2016.60247","volume":"2","author":"J Pogorzelska","year":"2016","unstructured":"Pogorzelska J, Flisiak R. Real-world experience with ombitasvir\/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection. Clin Exp Hepatol, 2016,2(2):34\u201337","journal-title":"Clin Exp Hepatol"},{"issue":"9986","key":"2363_CR17","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","volume":"385","author":"C H\u00e9zode","year":"2015","unstructured":"H\u00e9zode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet, 2015,385(9986):2502\u20132509","journal-title":"Lancet"},{"issue":"1","key":"2363_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S2468-1253(16)30002-4","volume":"1","author":"I Waked","year":"2016","unstructured":"Waked I, Shiha G, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol, 2016,1(1):36\u201344","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2363_CR19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology, 2006,43(6):1317\u20131325","journal-title":"Hepatology"},{"issue":"35","key":"2363_CR20","doi-asserted-by":"publisher","first-page":"8050","DOI":"10.3748\/wjg.v22.i35.8050","volume":"22","author":"CR Werner","year":"2016","unstructured":"Werner CR, Schwarz JM, Egetemeyr DP, et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol, 2016,22(35):8050\u20138059","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2363_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","volume":"151","author":"GN Ioannou","year":"2016","unstructured":"Ioannou GN, Beste LA, Chang MF, et al. Effectiveness of Sofosbuvir, Ledipasvir\/Sofosbuvir, or Paritaprevir\/Ritonavir\/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology, 2016,151(3):457\u2013471","journal-title":"Gastroenterology"},{"issue":"11","key":"2363_CR22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40261-017-0565-5","volume":"37","author":"H Ahmed","year":"2017","unstructured":"Ahmed H, Abushouk AI, Menshawy A, et al. Safety and efficacy of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with or without ribavirin for treatment of hepatitis C virus genotype 1: a systematic review and meta-analysis. Clin Drug Investig, 2017,37(11):1009\u20131023","journal-title":"Clin Drug Investig"},{"issue":"1","key":"2363_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/hep.26744","volume":"59","author":"DB Smith","year":"2014","unstructured":"Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology, 2014,59(1):318\u2013327","journal-title":"Hepatology"},{"issue":"3","key":"2363_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jhep.2015.04.023","volume":"63","author":"W Doss","year":"2015","unstructured":"Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol, 2015,63(3):581\u2013585","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"2363_CR25","doi-asserted-by":"publisher","first-page":"S722","DOI":"10.1016\/S0168-8278(17)31930-X","volume":"66","author":"M Manns","year":"2017","unstructured":"Manns M, Gane EJ, Willems BE, et al. The safety and tolerability of SOF\/VEL\/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis. J Hepatol, 2017,66(Suppl 1):S722\u2013S723","journal-title":"J Hepatol"},{"issue":"4","key":"2363_CR26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/hep.28706","volume":"64","author":"A Abergel","year":"2016","unstructured":"Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology, 2016,64(4):1049\u20131056","journal-title":"Hepatology"},{"key":"2363_CR27","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00705-020-04639-x","volume":"165","author":"EM Said","year":"2020","unstructured":"Said EM, Abdulaziz BA, El Kassas M, et al. High success rates for the use of sofosbuvir\/ombitasvir\/paritaprevir\/ritonavir + ribavirin and sofosbuvir\/simeprevir\/daclatasvir+ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir\/daclatasvir therapy: a real-life experience. Arch Virol, 2020,165:1633\u20131639","journal-title":"Arch Virol"},{"issue":"5","key":"2363_CR28","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s10620-018-5005-8","volume":"63","author":"A Abdel-Moneim","year":"2018","unstructured":"Abdel-Moneim A, Aboud A, Abdel-Gabbar M, et al. Retreatment Efficacy of Sofosbuvir\/Ombitasvir\/Paritaprevir\/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients. Dig Dis Sci, 2018,63(5):1341\u20131347","journal-title":"Dig Dis Sci"},{"issue":"2","key":"2363_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","volume":"147","author":"P Andreone","year":"2014","unstructured":"Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology, 2014,147(2):359\u2013365","journal-title":"Gastroenterology"},{"issue":"21","key":"2363_CR30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s00508-017-1268-x","volume":"129","author":"RE Stauber","year":"2017","unstructured":"Stauber RE, Fauler G, Rainer F, et al. Anti-HCV treatment with ombitasvir\/paritaprevir\/ritonavir \u00b1 dasabuvir is associated with increased bile acid levels and pruritus. Wiener klinische Wochenschrift, 2017,129(21):848\u2013851","journal-title":"Wiener klinische Wochenschrift"},{"issue":"3","key":"2363_CR31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1124\/jpet.106.102657","volume":"318","author":"MP McRae","year":"2006","unstructured":"McRae MP, Lowe CM, Tian X, et al. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther, 2006,318(3):1068\u20131075","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-021-2363-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-021-2363-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-021-2363-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:04:29Z","timestamp":1659089069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-021-2363-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["2363"],"URL":"https:\/\/doi.org\/10.1007\/s11596-021-2363-9","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"31 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}